MarketCap
Facebook
X
TelegramAkers Biosciences, Inc. Book Value 2011-2026 | AKER
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Akers Biosciences, Inc.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 76.5 M | 248 M | 395 M | 636 M | 119 M | 68.1 M | 131 M | 104 M | 30.8 M | -2.68 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 636 M | -2.68 M | 181 M |
Book Value of other stocks in the Medical instruments industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
243 K | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
8.24 B | $ 66.02 | 1.49 % | $ 13.1 B | USA |
 |
Glaukos Corporation
GKOS
|
656 M | $ 130.28 | 2.22 % | $ 7.45 B | USA |
 |
Luminex Corporation
LMNX
|
199 M | - | - | $ 1.75 B | USA |
 |
Alcon
ALC
|
22 B | $ 64.85 | 1.16 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
4.05 B | $ 141.74 | 2.75 % | $ 3.49 B | USA |
 |
Intuitive Surgical
ISRG
|
17.9 B | $ 406.55 | 1.09 % | $ 145 B | USA |
 |
iRhythm Technologies
IRTC
|
153 M | $ 103.33 | 1.52 % | $ 3.31 B | USA |
 |
LeMaitre Vascular
LMAT
|
394 M | $ 93.19 | 1.06 % | $ 2.11 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
257 M | - | - | $ 955 M | USA |
 |
Repro Med Systems
KRMD
|
17 M | $ 3.99 | 2.84 % | $ 184 M | USA |
 |
Cantel Medical Corp.
CMD
|
411 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
762 M | - | - | $ 282 M | USA |
 |
Merit Medical Systems
MMSI
|
1.58 B | $ 67.39 | 3.3 % | $ 3.99 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
388 M | - | -0.05 % | $ 10.3 B | USA |
 |
Masimo Corporation
MASI
|
1.05 B | $ 179.95 | - | $ 9.59 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
9.03 M | - | - | $ 28.6 M | USA |
 |
Microbot Medical
MBOT
|
77.6 M | $ 1.83 | -2.93 % | $ 83.8 M |  Israel |
 |
Varian Medical Systems, Inc.
VAR
|
66.7 M | - | -0.02 % | $ 16.3 B | USA |
 |
Milestone Scientific
MLSS
|
2.81 M | $ 0.34 | 0.32 % | $ 27.9 M | USA |
 |
electroCore
ECOR
|
-1.71 M | $ 8.2 | -5.7 % | $ 69.6 K | USA |
 |
Envista Holdings Corporation
NVST
|
5.68 B | $ 25.77 | 3.7 % | $ 4.33 B | USA |
 |
Haemonetics Corporation
HAE
|
2.4 B | $ 74.32 | 2.34 % | $ 3.51 B | USA |
 |
STERIS plc
STE
|
7.2 B | $ 202.3 | 1.45 % | $ 19.9 B | USA |
 |
Isoray
ISR
|
207 M | - | 0.03 % | $ 108 M | USA |
 |
STAAR Surgical Company
STAA
|
344 M | $ 29.07 | -0.51 % | $ 1.44 B | USA |
 |
Teleflex Incorporated
TFX
|
3.12 B | $ 126.51 | 1.21 % | $ 5.65 B | USA |
 |
InfuSystem Holdings
INFU
|
57.3 M | $ 9.16 | 4.81 % | $ 189 M | USA |
 |
Utah Medical Products
UTMD
|
119 M | $ 66.17 | 0.72 % | $ 214 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.34 B | $ 10.37 | 3.34 % | $ 2.07 B | USA |
 |
West Pharmaceutical Services
WST
|
3.18 B | $ 327.2 | 1.16 % | $ 23.7 B | USA |
 |
Pulse Biosciences
PLSE
|
80.7 M | $ 25.68 | 0.9 % | $ 1.73 B | USA |
 |
Retractable Technologies
RVP
|
74.4 M | $ 0.69 | 2.72 % | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
36.6 M | $ 63.85 | 5.61 % | $ 210 M | USA |
 |
Predictive Oncology
POAI
|
47.7 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
372 M | $ 26.05 | 1.82 % | $ 1.24 B | USA |
 |
Stereotaxis
STXS
|
18.7 M | $ 1.83 | 2.81 % | $ 166 M | USA |
 |
Baxter International
BAX
|
6.1 B | $ 19.94 | 2.84 % | $ 10.2 B | USA |
 |
ResMed
RMD
|
3.36 B | $ 188.16 | 1.0 % | $ 27.5 B | USA |
 |
AtriCure
ATRC
|
492 M | $ 28.04 | 3.37 % | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
13.7 M | $ 5.93 | -1.25 % | $ 263 M | USA |
 |
NeuroMetrix
NURO
|
14.3 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
183 M | $ 12.04 | 2.56 % | $ 492 M | USA |
 |
Becton, Dickinson and Company
BDX
|
55.3 B | $ 144.21 | 1.83 % | $ 41.5 B | USA |
 |
Nephros
NEPH
|
10.2 M | $ 3.27 | 2.19 % | $ 34.7 M | USA |
 |
OraSure Technologies
OSUR
|
341 M | $ 4.37 | -2.35 % | $ 321 M | USA |
 |
Repligen Corporation
RGEN
|
2.11 B | $ 131.64 | -1.43 % | $ 7.4 M | USA |